Company news

Puma Biotechnology Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor

September 19, 2022

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

September 10, 2022

Puma Biotechnology Reports Second Quarter 2022 Financial Results

August 3, 2022

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting

May 25, 2022

Puma Biotechnology Reports First Quarter 2022 Financial Results

May 4, 2022

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

April 20, 2022

Puma Biotechnology Announces $10 Million Private Placement

March 9, 2022

Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)

November 22, 2021

Puma Biotechnology Reports Third Quarter 2021 Financial Results

November 3, 2021

Puma Biotechnology Reports Second Quarter 2021 Financial Results

August 4, 2021

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital

July 25, 2021

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

June 30, 2021

Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting

June 3, 2021

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting

May 18, 2021

Puma Biotechnology Reports First Quarter 2021 Financial Results

May 5, 2021

Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China

February 24, 2021

Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020

January 28, 2021

Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS

December 10, 2020

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

December 8, 2020

Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

December 1, 2020

Puma Biotechnology Reports Third Quarter 2020 Financial Results

November 4, 2020

Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

November 4, 2020

Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

October 4, 2020

Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology

August 18, 2020

Puma Biotechnology Reports Second Quarter 2020 Financial Results

August 5, 2020

Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers

July 26, 2020

Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

July 22, 2020

Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer

July 15, 2020

Puma Biotechnology Reports First Quarter 2020 Financial Results

May 6, 2020

Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea

April 29, 2020

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

March 24, 2020

Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

February 25, 2020

CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries

December 1, 2019

Puma Biotechnology Reports Third Quarter 2019 Financial Results

November 5, 2019

FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

October 1, 2019

Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

September 10, 2019

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.